TABLE 1

Demographic Factors, Comorbidities, Medication, and Imaging Examinations of Study Participants According to Thyroid Cancer Status

			Thyroid cancer
	Control (n = 41,444)		All (n = 10,361)		Without ¹³¹I treatment (n = 3,292)		With ¹³¹I treatment (n = 7,069)
Variable	n	%	n	%	n	%	n	%	P
Age (y)									0.99
≤49	26,184	63.2	6,546	63.2	1,996	60.6	4,550	64.4
50–64	10,740	25.9	2,685	25.9	861	26.2	1,824	25.8
>65	4,520	10.9	1,130	10.9	435	13.2	695	9.83
Mean (SD)	46.0	14.3	46.2	13.9	47.2	14.7	45.7	13.5	0.17
CCI score									<0.001^*
0	38,642	93.2	9,429	91.0	2,915	88.6	6,514	92.2
1	1,812	4.37	630	6.08	235	7.14	395	5.59
2	514	1.24	183	1.77	80	2.43	103	1.46
3+	476	1.15	119	1.15	62	1.88	57	0.81
Obesity	643	1.55	283	2.73	78	2.37	205	2.90	<0.001
Alcohol-related illness	519	1.25	113	1.09	42	1.28	71	1.00	0.18
Diabetes	2,405	5.80	820	7.91	269	8.17	551	7.79	<0.001
Lung metastases	8	0.02	95	0.92	17	0.52	78	1.10	<0.001
Benign neoplasm of the breast	1,173	2.83	599	5.78	171	5.19	428	6.05	<0.001
Hormone therapy	12,443	30.0	3,627	35.0	1,074	32.6	2,553	36.1	<0.001
Mammography	3,412	8.23	1,406	13.6	409	12.4	997	14.1	<0.001
Ultrasonography	1,498	3.61	781	7.54	237	7.20	544	7.70	<0.001
Treatment
Radiotherapy			479	4.62	179	5.44	300	4.24	<0.001^†
Chemotherapy			240	2.32	112	3.40	128	1.81	<0.001^†
Thyroxine			6,960	67.2	1,771	53.8	5,189	73.4	<0.001^†

↵* Comparison between breast cancer and control.
↵† Comparison between thyroid cancer without ¹³¹I treatment and thyroid cancer with ¹³¹I treatment.